AMSBIO announces the launch of the QuicKey Pro™ range of ELISA kits – new easy-to-use assays that require just one step of washing, and one step of sample addition, resulting in a whole experiment taking only 90 minutes.
Compared with traditional ELISA kits, the total procedure time using a QuicKey Pro™ ELISA kit is reduced by 1-2 hours, resulting in significant gains in experimental efficiency.
AMSBIO has introduced further essential tools for SARS-CoV-2 researchers to help decipher the COVID-19 B.1.1.529 variant.
New to the AMSBIO range are recombinant proteins, easy-to-perform assay kits, Omicron pseudotyped lentiviruses and spike neutralizing antibodies for use in functional assays to block SARS-CoV-2 spike protein and ACE2 binding.
SOMERSET, N.J. – March 16, 2022 — Catalent, the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced the completion of a $30 million (€27 million) project at its facility in Limoges, France, to transform the site into a European center of excellence for biopharmaceutical development, drug product fill/finish services, and packaging.
Transaction expands BioIVT’s donor network and increases its capacity to provide fresh whole blood, plasma, serum, and red blood cells for drug and diagnostic development
BioIVT, a leading provider of biospecimens, research models and services for drug and diagnostic development, today announced that it has acquired Tennessee Blood Services (TBS), a commercial blood bank located in Memphis, Tennessee. TBS is FDA-registered to collect whole blood and blood products for diagnostic use by manufacturers and research facilities worldwide.
Cambridge, UK 4th April 2022– EVONETIX LTD (‘Evonetix’), the synthetic biology company bringing semiconductor technology to DNA synthesis, today announced it has been granted patent EP3551331B1 in Europe for its proprietary thermal control technology for DNA synthesis, as well as the design and manufacture of its silicon chips. This patent extends Evonetix’s IP portfolio and is a key step in the Company’s strategy to develop a benchtop DNA synthesis platform, to change how DNA is accessed, made, and used.
London, Friday 1ST April 2022: Reddie & Grose LLP, the internationally renowned firm of European and United Kingdom patent, trade mark and design attorneys, has today announced a raft of promotions including the creation of two new Partners and a number of Senior Associates. These promotions, which take effect from 1 April 2022, recognise the talent and expertise in patent law across a range of market sectors, including medical devices & digital healthcare.
Covid has put serendipitous collaboration at risk in the ‘city of ideas’
Thursday 31 March 2022, Cambridge, UK
New research has highlighted the challenge of maintaining innovation-fuelled growth in the new hybrid working environment.
At the One Nucleus Building Life Science Adventures careers conference on 2 March 2022, Dr. John McCafferty, CSO and Founder, IONTAS Limited and CEO and Founder of Maxion Therapeutics, was announced winner of the Life Sciences Inspiration of the Year Award, sponsored and presented by Johnson & Johnson Innovation. This award recognises an ambassador for the Life Sciences, someone who has shown great leadership in building teams and who is an inspiration to others and John has certainly gone above and beyond in achieving this.
Cambridge and London, UK, 29th March 2022: Mursla, a novel multi-omics exosome characterisation company, is pleased to announce that it has secured mentorship support from Roche Diagnostics Ltd for a new liquid biopsy prospective pilot study for liver cancer surveillance through MedCity’s Collaborate to Innovate: London Diagnostics programme. Liver cancer is the third most common cause of premature cancer death worldwide and its incidence has increased significantly over other forms of cancer in the last three decades.
tranScrip, the fast-growing contract drug development organisation which supports the development and lifecycle of medicines, has acquired Dublin-based Real Regulatory, a highly respected business specialising in European regulatory affairs, quality systems and compliance for medical products.